Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6376477B2 · kind B2 · utility
4Cited by
7References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2000 |
| Grant date | Apr 23, 2002 |
| Priority date | — |
| Expiry date | Dec 19, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/66
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The inhibition of natural bone formation experienced in the prophylaxis and/or treatment of bone resorption disease with a bisphosphonic acid or a pharmaceutically acceptable salt thereof is overcome by the concommitant administration of an agent that binds to the androgen receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.